Vaxcyte, Inc. announced it has appointed Carlos Paya and Michael Kamarck, accomplished industry leaders, to its board of directors. Dr. Paya will also serve as the board chair. Kurt von Emster, a longtime director who served as interim chair, will remain on the board. Dr. Paya currently holds a number of board positions and serves as the board chairman for Fluidigm and Highlight Therapeutics. Most recently, Dr. Paya served as the CEO and President of Immune Design Corp. Previously, he was the President of Elan Pharmaceuticals responsible for the Biopharmaceutical unit focused on neuroscience. Dr. Paya spent a number of years at Eli Lilly in roles of increasing responsibility, including Global Head for the Diabetes and Endocrine Franchise. Dr. Kamarck is the Chairman of the Sanofi Biotech Advisory Council. Dr. Kamarck recently retired as Chief Technology Officer for Vir Biotechnology, Inc. Previously, Dr. Kamarck was the Senior Vice President of Global Vaccines and Biologics Manufacturing and President of Merck BioVentures. In this role, he was responsible for the worldwide manufacturing network in support of the vaccine portfolio and biologics businesses. Dr. Kamarck also held numerous senior executive positions at Wyeth Pharmaceuticals, including President, Technical Operations and Product Supply as a member of the Wyeth Management Team. Dr. Kamarck also spent 16 years at Bayer AG serving in numerous roles, including Senior Vice President of Operations for Bayer Biologicals.
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
VAXCYTE, INC. 
